Can GLP-1 Weight Loss Drugs Also Treat Osteoarthritis? A Systematic Review
A systematic review found consistent evidence across preclinical and limited human studies that GLP-1 receptor agonists may protect cartilage, reduce joint inflammation, and relieve osteoarthritis pain.
Quick Facts
What This Study Found
This systematic review of 11 studies (7 preclinical, 4 human) found consistent signals that GLP-1 receptor agonists may protect cartilage, reduce inflammation, and relieve pain in osteoarthritis. Preclinical studies showed favorable chondroprotective and immunomodulatory effects with a dose-dependent response, primarily through inhibition of the NF-κB inflammatory pathway. The limited human studies supported these findings.
GLP-1 agonists were assessed for structural effects (cartilage protection), immunomodulation, analgesia, and molecular pathway effects in osteoarthritis. The evidence, while limited, was consistently positive across both animal and human studies.
Key Numbers
11 studies total · 7 preclinical · 4 human · structural effects (n=6 preclinical, n=1 human) · immunomodulation (n=7) · analgesia (n=1) · dose-dependent effect · NF-κB pathway inhibition
How They Did This
Systematic review searching Ovid Medline, Embase, and CINAHL from inception through November 2024. Three independent reviewers conducted risk of bias assessment and data extraction. Qualitative evidence synthesis was performed. Prospectively registered on PROSPERO (two registrations). Included studies examining GLP-1 receptor agonists and osteoarthritis outcomes in both preclinical and human settings.
Why This Research Matters
Osteoarthritis affects hundreds of millions of people worldwide and has no disease-modifying treatment. With millions already taking GLP-1 drugs for weight loss and diabetes, discovering that these same drugs may directly protect joints — beyond just reducing weight-related joint stress — could be transformative. The NF-κB inhibition mechanism suggests genuine anti-inflammatory action in joints, not just a secondary benefit of weight loss.
The Bigger Picture
Osteoarthritis is the most common joint disease worldwide, and there is no drug that stops or reverses cartilage damage. If GLP-1 agonists — which are already being taken by millions for other conditions — turn out to directly protect joints and reduce inflammation, it would represent the first disease-modifying treatment for osteoarthritis. This review provides the rationale for launching larger human trials to test this hypothesis rigorously.
What This Study Doesn't Tell Us
Only 11 studies met inclusion criteria, with just 4 in humans. The evidence base is too small for meta-analysis. Human studies were limited in design quality and sample size. Weight loss from GLP-1 drugs confounds the ability to determine whether joint benefits are direct or mediated through reduced mechanical load. High-quality randomized controlled trials are needed.
Questions This Raises
- ?Are the joint benefits of GLP-1 drugs driven by direct anti-inflammatory effects on cartilage, or primarily by weight loss reducing mechanical stress?
- ?Which specific GLP-1 agonist (semaglutide, liraglutide, tirzepatide) shows the strongest osteoarthritis benefit?
- ?At what dose and duration would GLP-1 drugs need to be used to produce meaningful osteoarthritis outcomes in humans?
Trust & Context
- Key Stat:
- Consistent signals across all 11 studies Every study reviewed — whether in animals or humans — showed favorable effects of GLP-1 drugs on osteoarthritis outcomes, from cartilage protection to pain relief, suggesting a real biological effect rather than random findings.
- Evidence Grade:
- Rated low because while the systematic review methodology is rigorous (PROSPERO-registered, three independent reviewers), the underlying evidence consists of mostly preclinical studies with only 4 human studies, none of which appear to be large randomized controlled trials.
- Study Age:
- Published in 2025 with literature searched through November 2024. This is a very current review capturing the emerging interest in GLP-1 drugs for osteoarthritis, a rapidly growing research area.
- Original Title:
- Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies.
- Published In:
- Osteoarthritis and cartilage open, 7(1), 100567 (2025)
- Database ID:
- RPEP-10435
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Could taking Ozempic or Mounjaro help my arthritis?
Early evidence is promising — both animal and human studies suggest GLP-1 drugs may protect cartilage and reduce joint inflammation directly, beyond the benefits of weight loss. However, the evidence is still limited and these drugs are not approved for osteoarthritis. Talk to your doctor before using them specifically for joint issues.
How would GLP-1 drugs protect joints?
The preclinical studies suggest GLP-1 drugs inhibit the NF-κB pathway — a master switch for inflammation — inside joint tissues. This appears to reduce cartilage breakdown and immune-mediated damage in a dose-dependent manner, independent of weight loss effects.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10435APA
Cheng, Jacinta; Solomon, Tia; Estee, Mahnuma; Cicuttini, Flavia M; Lim, Yuan Z. (2025). Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies.. Osteoarthritis and cartilage open, 7(1), 100567. https://doi.org/10.1016/j.ocarto.2025.100567
MLA
Cheng, Jacinta, et al. "Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies.." Osteoarthritis and cartilage open, 2025. https://doi.org/10.1016/j.ocarto.2025.100567
RethinkPeptides
RethinkPeptides Research Database. "Effect of glucagon-like peptide-1 receptor agonists in osteo..." RPEP-10435. Retrieved from https://rethinkpeptides.com/research/cheng-2025-effect-of-glucagonlike-peptide1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.